SWOG S1512 trial sees high response rate to pembrolizumab in patients with unresectable desmoplastic melanoma

SWOG S2302 Pragmatica-Lung study opens to enrollment, a model for easier, more representative clinical trials

Combined long-term survival results from NRG Oncology RTOG 0630 and the ancillary analysis of the combined NRG-RTOG 0630/9514 trials indicate that pathologic complete response is associated with improved survival outcomes for patients with localized soft tissue sarcoma who receive preoperative chemoradiotherapy or radiotherapy

The NRG-GY018 clinical trial comparing pembrolizumab combined with standard of care chemotherapy followed by maintenance pembrolizumab to placebo combined with chemotherapy followed by placebo indicated that patients with stage III-IV or recurrent endometrial cancer who received pembrolizumab exhibited improved progression-free survival outcomes

The GOG-0240 clinical trial demonstrated that the incorporation of bevacizumab with chemotherapy resulted in a statistically significant and clinically meaningful survival benefit for women with recurrent and metastatic cervical carcinoma

Results from the NRG-GY017 randomized trial comparing the anti-PD-L1 inhibitor atezolizumab before and concurrent with chemoradiation indicated favorable outcomes for 2-year disease-free survival and demonstrated evidence of improved immunogenicity with neoadjuvant atezolizumab in patients with locally advanced cervical cancer

Results from the NRG-GOG-0279 clinical study indicate that women with locally advanced squamous cell carcinoma of the vulva who received gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy exhibited increased rate of pathologic complete responses

Dr. Isabelle Bedrosian is the newly appointed director of the Alliance Program for Procedure-Based Therapy

NRG Oncology recently announced that they have named three health equity fellows as a part of the organization’s Health Equity Fellowship Program